These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 17169651)

  • 21. The continued debate: intermittent vs. continuous hormonal ablation for metastatic prostate cancer.
    Gleave M; Klotz L; Taneja SS
    Urol Oncol; 2009; 27(1):81-6. PubMed ID: 19111804
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduction of irradiation volume and toxicities with 3-D radiotherapy planning over conventional radiotherapy for prostate cancer treated with long-term hormonal therapy.
    Yamazaki H; Nishiyama K; Tanaka E; Maeda O; Meguro N; Kinouchi T; Usami M; Kakimoto K; Ono Y; Nishimura T
    Anticancer Res; 2008; 28(6B):3913-20. PubMed ID: 19192649
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intermittent hormone therapy and its place in the contemporary endocrine treatment of prostate cancer.
    Shaw G; Oliver RT
    Surg Oncol; 2009 Sep; 18(3):275-82. PubMed ID: 19269165
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A national survey of medical students' beliefs and knowledge in screening for prostate cancer.
    Marcella S; Delnevo CD; Coughlin SS
    J Gen Intern Med; 2007 Jan; 22(1):80-5. PubMed ID: 17351844
    [TBL] [Abstract][Full Text] [Related]  

  • 25. American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer.
    Basch EM; Somerfield MR; Beer TM; Carducci MA; Higano CS; Hussain MH; Scher HI;
    J Clin Oncol; 2007 Nov; 25(33):5313-8. PubMed ID: 17925542
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Urologists' use of intensity-modulated radiation therapy for prostate cancer.
    Mitchell JM
    N Engl J Med; 2013 Oct; 369(17):1629-37. PubMed ID: 24152262
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Urologists' self-referral for pathology of biopsy specimens linked to increased use and lower prostate cancer detection.
    Mitchell JM
    Health Aff (Millwood); 2012 Apr; 31(4):741-9. PubMed ID: 22492891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hormone-refractory prostate cancer: a primer for the primary care physician.
    Potvin K; Winquist E
    Can J Urol; 2008 Aug; 15 Suppl 1():14-20; discussion 20. PubMed ID: 18700061
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differing perceptions of quality of life in patients with prostate cancer and their doctors.
    Sonn GA; Sadetsky N; Presti JC; Litwin MS
    J Urol; 2009 Nov; 182(5):2296-302. PubMed ID: 19758610
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE.
    Abouassaly R; Paciorek A; Ryan CJ; Carroll PR; Klein EA
    Cancer; 2009 Oct; 115(19):4470-6. PubMed ID: 19637339
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcome measurements in scleroderma: results from a delphi exercise.
    Gazi H; Pope JE; Clements P; Medsger TA; Martin RW; Merkel PA; Kahaleh B; Wollheim FA; Baron M; Csuka ME; Emery P; Belch JF; Hayat S; Lally EV; Korn JH; Czirjak L; Herrick A; Voskuyl AE; Bruehlmann P; Inanc M; Furst DE; Black C; Ellman MH; Moreland LW; Rothfield NF; Hsu V; Mayes M; McKown KM; Krieg T; Siebold JR
    J Rheumatol; 2007 Mar; 34(3):501-9. PubMed ID: 17299843
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluating a decision aid for patients with localized prostate cancer in clinical practice.
    Isebaert S; Van Audenhove C; Haustermans K; Junius S; Joniau S; De Ridder K; Van Poppel H
    Urol Int; 2008; 81(4):383-8. PubMed ID: 19077396
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Attitudes and use of alternative therapies in UK prostate cancer patients-isn't it time we were in the know?
    Cheetham PJ; Le Monnier KJ; Brewster SF
    Prostate Cancer Prostatic Dis; 2001; 4(4):235-241. PubMed ID: 12497025
    [TBL] [Abstract][Full Text] [Related]  

  • 34. What the prostate cancer patient should know: variations in urologists' opinions.
    Feldman-Stewart D; Brundage MD; Hayter C; Davidson JR; Groome P; Nickel JC
    Can J Urol; 1997 Dec; 4(4):438-444. PubMed ID: 12735808
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Who works in the prevention and early detection of benign prostatic hyperplasia and prostate cancer in Croatia?].
    Kranjcević K; Marković BB
    Acta Med Croatica; 2007 Feb; 61(1):45-8. PubMed ID: 17593640
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current controversies in the treatment of high-risk prostate cancer.
    Mitchell RE; Chang SS
    Curr Opin Urol; 2008 May; 18(3):263-8. PubMed ID: 18382235
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy.
    Sarosdy MF
    Cancer; 2007 Feb; 109(3):536-41. PubMed ID: 17183557
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Venous thromboembolism and cyproterone acetate in men with prostate cancer: a study using the General Practice Research Database.
    Seaman HE; Langley SE; Farmer RD; de Vries CS
    BJU Int; 2007 Jun; 99(6):1398-403. PubMed ID: 17537215
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Screening for prostate cancer in U.S. men ACPM position statement on preventive practice.
    Lim LS; Sherin K;
    Am J Prev Med; 2008 Feb; 34(2):164-70. PubMed ID: 18201648
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
    Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.